The Editor in Chief of Clinical Medical Insights: Oncology, Dr William C S Cho, has awarded an endorsement to 'Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?'
In the endorsement the Editor in Chief writes:
Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape.
To read more visit the article now: Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T
Posts
